Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the subject application, and please amend the claims as follows:

Claims 1-30. (Canceled)

Claim 31. (Currently amended): A system for depositing an embolic material in a perigraft space between an endovascular graft and a body lumen wall, the system comprising:

an endovascular graft comprising a generally tubular body having a proximal end and a distal end, a proximal inflatable cuff disposed at or near the proximal end of the body, a distal inflatable cuff disposed at or near the distal end of the body and an inflatable channel in fluid communication with the proximal and distal cuffs;

a delivery device configured to access ~~the~~ perigraft space between the endovascular graft and a body lumen wall;

an occlusion assembly that is configured to substantially reduce a blood flow through the endovascular graft; and

a curable embolic material that is delivered to the perigraft space with the delivery device, wherein the embolic material comprises polyethylene glycol diacrylate, pentaerythritol tetra 3(mercaptopropionate), and a buffer;

wherein the polyethylene glycol diacrylate comprises a molecular weight between 700 and 800.

Claim 32. (Original): The system of claim 31 wherein the occlusion assembly comprises an occlusion member positioned adjacent a distal end of a guidewire.

Claim 33. (Original): The system of claim 32 wherein the occlusion member is an expandable balloon.

Claim 34. (Withdrawn): The system of claim 31 wherein the delivery device comprises a syringe.

Claim 35. (Original): The system of claim 31 wherein the delivery device comprises a catheter.

Claim 36. (Original): The system of claim 31 wherein the embolic material is radiopaque.

Claim 37. (Previously presented): The system of claim 31 wherein the buffer comprises glycylglycine.

Claim 38. (Original): The system of claim 37 wherein the glycylglycine buffer is in a proportion ranging from about 5 to about 40 weight percent.

Claim 39. (Withdrawn): The system of claim 37 wherein the buffer comprises HEPES.

Claim 40. (Original): The system of claim 37 wherein the polyethylene glycol diacrylate is in a proportion ranging from about 50 to about 55 weight percent.

Claim 41. (Previously presented): The system of claim 37 wherein the polyethylene glycol diacrylate consists essentially of polyethylene glycol diacrylate having a molecular weight between 700 and 800.

Claim 42. (Previously presented): The system of claim 41 wherein the pentaerythritol tetra 3(mercaptopropionate) is in a proportion ranging from about 0.31 to about 0.53 times the weight percent of the polyethylene glycol diacrylate present.

Claim 43. (Original): The system of claim 37 wherein the embolic material further comprises saline or other inert biocompatible materials.

Claim 44. (Original): The system of claim 31 wherein the embolic material has a first viscosity upon delivery into the perigraft space and is a solid after the embolic material has substantially cured.

Claim 45. (Currently amended): A kit for depositing an embolic material in a perigraft space between an endovascular graft and a body lumen wall, the kit comprises:

an endovascular graft comprising a generally tubular body having a proximal end and a distal end, a proximal inflatable cuff disposed at or near the proximal end of the body, a distal inflatable cuff disposed at or near the distal end of the body and an inflatable channel in fluid communication with the proximal and distal cuffs;

a delivery device configured to access ~~the~~ perigraft space between the endovascular graft and a body lumen wall; and

a curable embolic material comprising polyethylene glycol diacrylate, pentaerythritol tetra 3(mercaptopropionate), and a buffer;

wherein the polyethylene glycol diacrylate comprises a molecular weight between 700 and 800.

Claim 46. (Original): The kit of claim 45 wherein the delivery device comprises a catheter.

Claim 47. (Withdrawn): The kit of claim 45 wherein the delivery device comprises a syringe and needle configured to percutaneously access the perigraft space.

Claim 48. (Original): The kit of claim 45 wherein the buffer comprises a glycylglycine buffer.

Claim 49. (Original): The kit of claim 48 wherein the glycylglycine buffer is present in a proportion ranging from about 5 to about 40 weight percent.

Claim 50. (Original): The kit of claim 45 wherein the polyethylene glycol diacrylate is present in a proportion ranging from about 50 to about 55 weight percent.

Claim 51. (Previously presented): The kit of claim 45 wherein the polyethylene glycol diacrylate consists essentially of polyethylene glycol diacrylate having a molecular weight between 700 and 800.

Claim 52. (Previously presented): The kit of claim 51 wherein the pentaerythritol tetra 3(mercaptopropionate) is present in a proportion ranging from about 0.31 to about 0.53 times the weight percent of the polyethylene glycol diacrylate present.

Claim 53. (Original): The kit of claim 45 further comprising an occlusion member that is configured to temporarily occlude the body lumen.

Claim 54. (Original): The kit of claim 53 wherein the occlusion member is an inflatable balloon.

Claim 55. (Withdrawn): The kit of claim 45 wherein the buffer comprises HEPES.

Claim 56. (Currently amended): A system for depositing an embolic material in a perigraft space between an endovascular graft and a body lumen wall, the system comprising:

an endovascular graft comprising a generally tubular body having a proximal end and a distal end, a proximal inflatable cuff disposed at or near the proximal end of the body, a distal

inflatable cuff disposed at or near the distal end of the body and an inflatable channel in fluid communication with the proximal and distal cuffs;

a delivery device configured to access ~~the~~ perigraft space between the endovascular graft and a body lumen wall;

an occlusion assembly that is configured to substantially reduce a blood flow through the endovascular graft; and

a curable embolic material that is delivered to the perigraft space with the delivery device, wherein the embolic material comprises polyethylene glycol diacrylate, pentaerythritol tetra 3(mercaptopropionate), and a buffer;

wherein the polyethylene glycol diacrylate comprises a molecular weight between 700 and 800;

wherein the pentaerythritol tetra 3(mercaptopropionate) is in a proportion ranging from about 0.31 to about 0.53 times the weight percent of the polyethylene glycol diacrylate present; and

wherein the buffer comprises glycylglycine or HEPES.

Claim 57. (Previously presented): The system of claim 56 wherein the occlusion assembly comprises an occlusion member positioned adjacent a distal end of a guidewire.

Claim 58. (Previously presented): The system of claim 56 wherein the occlusion member is an expandable balloon.

Claim 59. (Previously presented): The system of claim 56 wherein the delivery device comprises a catheter.

Claim 60. (Previously presented): The system of claim 56 wherein the embolic material is radiopaque.

Claim 61. (Previously presented): The system of claim 56 wherein the glycylglycine buffer is in a proportion ranging from about 5 to about 40 weight percent.

Claim 62. (Previously presented): The system of claim 56 wherein the polyethylene glycol diacrylate is in a proportion ranging from about 50 to about 55 weight percent.

Claim 63. (Previously presented): The system of claim 56 wherein the polyethylene glycol diacrylate consists essentially of polyethylene glycol diacrylate having a molecular weight between 700 and 800.

Claim 64. (Previously presented): The system of claim 56 wherein the embolic material further comprises saline or other inert biocompatible materials.

Claim 65. (Previously presented): The system of claim 56 wherein the embolic material has a first viscosity upon delivery into the perigraft space and is a solid after the embolic material has substantially cured.